NANO Nanobiotix SA

NANOBIOTIX to Participate in Jefferies London Healthcare Conference

NANOBIOTIX to Participate in Jefferies London Healthcare Conference

PARIS and CAMBRIDGE, Mass., Nov. 11, 2025 (GLOBE NEWSWIRE) -- (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in a fireside chat at the following conference:

Jefferies London Healthcare Conference

Date: Monday, November 17, 2025

Time: 3pm GMT / 10am ET / 4pm CET

Location: London, UK

Presenters: Laurent Levy, Chief Executive Officer of Nanobiotix and Bart van Rhijn, Chief Financial & Business Officer of Nanobiotix

Webcast link:

The fireside chat will be webcast live from the of the Investors section of the Company’s website. Replay of the webcast will be available following the event.

About NANOBIOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.

Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.

Nanobiotix is the owner of more than 25 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.

For more information about Nanobiotix, visit us at or follow us on and .

Contacts

Nanobiotix
Communications Department

Brandon Owens

VP, Communications

+1 (617) 852-4835

Investor Relations Department



Joanne Choi

VP, Investor Relations (US)

+1 (713) 609-3150



Ricky Bhajun

Director, Investor Relations (EU)

+33 (0) 79 97 29 99







Media Relations


France – HARDY

Caroline Hardy

50







Global – uncapped

Becky Lauer

+1 (646) 286-0057





Attachment



EN
11/11/2025

Underlying

NANONanobiotix SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nanobiotix SA

 PRESS RELEASE
Free
NANO NANOBIOTIX SA

Information mensuelle relative au nombre total de droits de vote et d...

Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social Conformément aux articles L.233-8 II du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers PARIS, 13 janv. 2026 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Paris / NasdaqEuronext Compartiment : B Code ISIN : FR0011341205Nasdaq : NBTXBloomberg : NANO:FPReuters : NANO.PASite web : DateNombre total d’actions composant le capital socialNombre total de droits de voteTotal théorique1Total exerçable231 décembre 202548 410 06850 109 17050 087 052 À p...

January 13, 2026 1 EN
 PRESS RELEASE
Free
NANO NANOBIOTIX SA

Voting Rights and Shares Capital of the Company

Voting Rights and Shares Capital of the Company In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Market: Euronext Paris / NasdaqEuronext Compartment: B ISIN code: FR0011341205Nasdaq: NBTXBloomberg: NANO:FPReuters: NANO.PAWebsite: DateNumber of Shares OutstandingTotal number of voting rightsTotal voting rights, theoretical1Total voting rights,exercisable2December 31, 202548,410,06850,109,17050,087,052 About NANOBI...

January 13, 2026 1 EN
Khouloud Ben Aziza ... (+2)
  • Khouloud Ben Aziza
  • Martial Descoutures
NANO NANOBIOTIX SA

Nanobiotix : Les dernières données cliniques renforcent la thèse d’inv...

Les données récentes (phase 1) dans le mélanome, le cancer du pancréas ou le cancer de la tête et du cou avec anti-PD1 (1e ou 2nd L) renforcent, selon nous, l’action locale ainsi que l’action systémique de JNJ-1900/NBTXR3. Ces résultats confirment ce qui a déjà été observé dans les précédentes études cliniques et soutiennent la thèse selon laquelle le candidat médicament pourrait devenir une « backbone therapy » en oncologie. Le risk/reward nous semble particulièrement attractif sur ces niveaux ...

01/06/26 January 6, 2026 1 FR
 PRESS RELEASE
Free
NANO NANOBIOTIX SA

Voting Rights and Shares Capital of the Company

Voting Rights and Shares Capital of the Company In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Market: Euronext Paris / NasdaqEuronext Compartment: B ISIN code: FR0011341205Nasdaq: NBTXBloomberg: NANO:FPReuters: NANO.PAWebsite: DateNumber of Shares OutstandingTotal number of voting rightsTotal voting rights, theoretical1Total voting rights,exercisable2November 30, 202548,401,11850,101,69950,079,581 About NANOBIOTI...

December 17, 2025 1 EN
 PRESS RELEASE
Free
NANO NANOBIOTIX SA

Information mensuelle relative au nombre total de droits de vote et d’...

Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social Conformément aux articles L.233-8 II du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers PARIS, 17 déc. 2025 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Paris / NasdaqEuronext Compartiment : B Code ISIN : FR0011341205Nasdaq : NBTXBloomberg : NANO:FPReuters : NANO.PASite web : DateNombre total d’actionscomposant le capitalsocialNombre total de droits de voteTotal théorique1Total exerçable230 novembre 202548 401 11850 101 69950 079 581 À propos...

December 17, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch